JPRN-jRCT2080220654UnknownPhase 1
Phase I, open label, dose ascending study of BCX1777 (oral) in patients with recurrent or refractory T/NK-cell malignancies
Mundipharma K.K.0 sites24 target enrollmentStarted: January 8, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria (excerpted)
- •- Histologically documented with histopathological diagnosis from biopsy, T/NK-cell malignancies (WHO classification). Precursor T-cell lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) should be excluded in this study
- •- A patient with recurrent, relapse or refractory T/NK-cekk malignancies who has received at lease one chemotherapeutic regimen
Exclusion Criteria
- •Exclusion criteria (excerpted)
- •- Pregnant, breast-feeding female, female with a possibility of becoming pregnant (fertile female; in the case of female before menopause or within a year from menopause, the patient sho is positive in the pregnancy test conducted within 14 days before the start of administration), or male and fertile female unwilling to practice appropriate contraception during the 2 mounths after the final administration.
- •- Active serious infection not controlled by oral or intravenous antibiotics.
Investigators
Similar Trials
Completed
Phase 1
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell MalignanciesRecurrent or Refractory T/NK-cell MalignanciesNCT00823355Mundipharma K.K.24
Active, not recruiting
Phase 1
A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors.--------------------------------------------------------Estudio abierto de fase 1b/2 con escalada de dosis de AMG 655 en combinación con AMG 479 en sujetos con tumores sólidos refractarios y avanzados.Part 1: Advanced, treatment-refractory solid tumorsPart 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma.------------------------------------------------------------Parte 1:tumores sólidos refractarios y avanzados.Parte 2:Cáncer de pulmón no microcítico avanzado (CPNM), cáncer colorrectal (CRC), cáncer pancreático, cáncer de ovario o sarcoma.MedDRA version: 9.1Level: LLTClassification code 10061451Term: Colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10033604Term: Pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-005074-12-ESAmgen Inc108
Recruiting
Not Applicable
A Phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumorsc-MET dependend solid tumors10027656NL-OMON43929ovartis16
Active, not recruiting
Phase 1
A study of GB5121 in adults with cancer of the central nervous system that has reappeared or did not respond to prior therapyRelapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphomaMedDRA version: 21.0Level: PTClassification code 10007953Term: Central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10036685Term: Primary central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006234-39-SEGB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Active, not recruiting
Phase 1
A study of GB5121 in adults with cancer of the central nervous system that has reappeared or did not respond to prior therapyRelapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphomaMedDRA version: 21.0Level: PTClassification code 10007953Term: Central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10036685Term: Primary central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006234-39-NLGB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.143